Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01164709
Other study ID # SAKK 65/08
Secondary ID SWS-SAKK-65/08EU
Status Completed
Phase Phase 1
First received
Last updated
Start date July 2010
Est. completion date November 2013

Study information

Verified date May 2019
Source Swiss Group for Clinical Cancer Research
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: Nelfinavir mesylate and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Bortezomib may also stop the growth of hematologic cancer by blocking blood flow to the cancer. Giving nelfinavir mesylate together with bortezomib may kill more cancer cells.

PURPOSE: This phase I trial is studying the side effects and best dose of nelfinavir mesylate when given together with bortezomib in treating patients with relapsed or progressive advanced hematologic cancer.


Description:

OBJECTIVES:

- To assess the safety of nelfinavir mesylate in combination with bortezomib in patients with relapsed or progressive, advanced hematologic malignancies.

- To establish the phase II recommended dose of nelfinavir mesylate in these patients.

OUTLINE: This is a multicenter, dose-escalation study of nelfinavir mesylate.

Patients receive oral nelfinavir mesylate twice daily on days 1-21 and bortezomib IV on days 8, 11, 15, and 18 in course 1. Course 1 has a duration of 28 days. Beginning in course 2, patients receive oral nelfinavir mesylate twice daily on days 1-14 and bortezomib IV on days 1, 4, 8, and 11. Treatment repeats every 21 days for 2 courses. Patients with responding disease may continue to receive nelfinavir mesylate and bortezomib for up to 4 additional courses.

After completion of study treatment, patients are followed for 30 days.


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date November 2013
Est. primary completion date July 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility DISEASE CHARACTERISTICS:

- Diagnosed with advanced hematologic malignancies meeting the following criteria:

- Multiple myeloma

- Received = 2 lines of prior chemotherapy (induction chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant with or without maintenance therapy is considered one line of therapy)

- Acute myeloid leukemia

- Acute lymphoblastic leukemia

- Diffuse large B-cell lymphoma

- Hodgkin lymphoma

- Mantle cell lymphoma

- Mature T- and NK-cell neoplasms restricted to the following WHO-defined entities:

- T-cell prolymphocytic leukemia

- T-cell large granular lymphocytic leukemia

- Aggressive NK-cell leukemia

- Adult T-cell leukemia/lymphoma

- Extranodal NK/T-cell lymphoma (nasal type)

- Mycosis fungoides

- Sézary syndrome

- Primary CD30-positive T-cell lymphoproliferative disorders

- Primary cutaneous anaplastic large cell lymphoma

- Primary cutaneous gamma-delta T-cell lymphoma

- Peripheral T-cell lymphoma (not otherwise specified)

- Angioimmunoblastic T-cell lymphoma

- Anaplastic large cell lymphoma (ALK-positive/ALK-negative)

- Grade 3B follicular lymphoma

- Relapsed following or progressed during standard therapy

- Meeting the following criteria:

- Standard intensive therapy is not feasible

- Current disease state for which there is no standard effective therapy

- Refused standard therapy where no curative option exists

- Measurable disease, defined as the following:

- Myeloma: measurable serum monoclonal protein > 1 g/dL for IgG, or > 0.5 g/dL for IgA, IgM or IgD, or difference between involved and uninvolved free light chain levels in serum > 100 mg/L

- Lymphoma: must have = 1 lesion measurable by CT (longest diameter = 15 mm)

- Acute leukemia: = 20% blasts in bone marrow or in peripheral blood (= 200/mL blasts in peripheral blood)

- No HIV-associated lymphoma

PATIENT CHARACTERISTICS:

- WHO performance status 0-2

- Absolute neutrophil count = 1,500/mm³

- Platelet count = 75,000/mm³ (if bone marrow impairment, = 20,000/mm^3)

- Hemoglobin > 80 g/L (if considered to be caused by the underlying hematologic malignancy or bone marrow impairment, > 80 g/L after transfusion)

- Bilirubin = 1.5 times upper limit of normal (ULN) (if suspected hemolysis, direct bilirubin = 1.5 times ULN)

- ALT = 2.5 times ULN

- Calculated creatinine clearance > 30 mL/min

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for 12 months after completion of study treatment

- Willing and capable to comply with an oral regimen

- Capable of understanding information given by the investigator on the trial

- Able to adhere and remain in geographic proximity to allow proper staging, treatment, and followup

- No other non-hematologic malignancy within the past 5 years, except adequately treated cervical carcinoma in situ or localized nonmelanoma skin cancer

- No known chronic hepatitis B or C infection or known HIV infection

- No serious underlying medical condition (at the judgment of the investigator) which would impair the ability of the patient to participate in the trial, including any of the following:

- Active autoimmune disease

- Uncontrolled diabetes

- Ongoing or active infection

- Symptomatic congestive heart failure

- Unstable angina pectoris

- Cardiac arrhythmia

- Psychiatric disorder

- No myocardial infarction within the past 6 months

- No polyneuropathy > grade 1 significantly interfering with activities of daily living or painful polyneuropathy

- No known hypersensitivity to trial drugs or hypersensitivity to any other component of the trial drugs

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- No more than 4 prior lines of chemotherapeutic regimens (induction chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant with or without maintenance therapy is considered one line of therapy)

- More than 30 days since prior treatment in a clinical trial

- More than 30 days since prior and no concurrent chemotherapy or biologic agents

- For patients with acute leukemia, hydroxyurea may be given up to 48 hours before first administration of the trial treatment, and low dose cytarabine (up to 20 mg/m^2) and mitoxantrone up to 20 mg up to 14 days before first dosing

- At least 1 week since prior and no concurrent CYP3A4 modulators

- No concurrent other experimental drugs

- No concurrent radiotherapy

- No concurrent antineoplastic therapy with chemotherapeutic or biologic agents

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
bortezomib
Bortezomib i.v., day 8, 11, 15, 18; 1.3 mg/m2
nelfinavir mesylate
p.o., days 1 to 21; dose level: (625), 1250, 1875, or 2500 mg, 2x/d

Locations

Country Name City State
Switzerland Inselspital Bern Bern
Switzerland Kantonsspital Graubuenden Chur
Switzerland Centre Hospitalier Universitaire Vaudois Lausanne
Switzerland Kantonsspital - St. Gallen St. Gallen

Sponsors (1)

Lead Sponsor Collaborator
Swiss Group for Clinical Cancer Research

Country where clinical trial is conducted

Switzerland, 

References & Publications (1)

Driessen C, Kraus M, Joerger M, Rosing H, Bader J, Hitz F, Berset C, Xyrafas A, Hawle H, Berthod G, Overkleeft HS, Sessa C, Huitema A, Pabst T, von Moos R, Hess D, Mey UJ. Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Dose limiting toxicity during first cycle
Secondary Objective response during treatment
Secondary Adverse events according to NCI CTCAE v.4.0 during treatment + 30 days
See also
  Status Clinical Trial Phase
Recruiting NCT05540340 - A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant Phase 1
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Completed NCT00001512 - Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Completed NCT01410630 - FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
Active, not recruiting NCT04270266 - Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma N/A
Terminated NCT00801931 - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders Phase 1/Phase 2
Completed NCT01949883 - A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma Phase 1
Completed NCT01682226 - Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies Phase 2
Completed NCT00003270 - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Phase 2
Recruiting NCT05019976 - Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma N/A
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Completed NCT04434937 - Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) Phase 2
Completed NCT01855750 - A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Phase 3
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Terminated NCT00775268 - 18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma Phase 1/Phase 2
Active, not recruiting NCT04188678 - Resiliency in Older Adults Undergoing Bone Marrow Transplant N/A
Terminated NCT00014560 - Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Phase 1
Recruiting NCT04977024 - SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer Phase 2
Active, not recruiting NCT03936465 - Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer Phase 1